#Italy #Milan #Newronika #AlphaDBS #Keith Carlton

Newronika Strengthens Leadership with New Appointment

Newronika, a leader in adaptive deep brain stimulation technology known as AlphaDBS™, has officially announced the appointment of Keith Carlton as its new Executive Chairman. This strategic decision aims to reinforce the company's leadership as it embarks on its next phase of global expansion.

A Step Toward Growth and Innovation

Mr. Carlton brings a wealth of experience in the medical device and neuromodulation sectors, where he has consistently driven innovation and operational excellence. His proven track record positions him well to guide Newronika as it seeks to enhance the clinical validation and commercialization of its proprietary adaptive deep brain stimulation system, AlphaDBS.

Lorenzo Rossi, PhD, co-founder and CEO of Newronika, expressed enthusiasm about Carlton’s arrival, stating, "We are honored to welcome Keith as our Executive Chairman. His strategic foresight and excellent track record in scaling innovative med-tech companies will be crucial as we push forward with our innovative therapies for addressing Parkinson's disease and minimizing side effects for patients."

Commitment to Patient-Centered Solutions

Carlton’s leadership is expected to facilitate a new era of innovation at Newronika. He has expressed excitement about joining the team at such a pivotal moment, acknowledging the potential of the company’s cutting-edge adaptive DBS technology to redefine treatment standards for Parkinson’s and other neurological disorders. He stated, "I look forward to collaborating with the board and our talented team to accelerate innovation, expand patient access, and have a meaningful global impact, starting with supporting the successful launch of our Phase III pivotal study in the USA."

As Newronika continues to build upon their recent achievements—including the CE mark for AlphaDBS, receiving IDE approval from the US FDA, and successfully completing a Series B funding round of 13.6 million euros—Carlton’s appointment solidifies their leadership foundation as they aim to transform neuromodulation therapies.

About Newronika

Founded as a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, Newronika is dedicated to revolutionizing deep brain stimulation through adaptive technology that optimizes therapy using real-time neurophysiological feedback. The company, headquartered in Milan, Italy, is committed to developing adaptive DBS with regulatory approvals and clinical initiatives across Europe, the US, and beyond.

As Newronika positions itself for growth under Carlton’s leadership, the medical technology community is keenly observing its advancements in transforming the treatment landscape for neurological disorders globally. The appointment not only elevates the company’s strategic capabilities but also reaffirms its dedication to improving the lives of patients worldwide with innovative solutions.

For further inquiries or information, please reach out to Lorenzo Rossi, PhD, co-founder and CEO at Newronika, or visit their website at Newronika.